Frequently asked questions about KBI Biopharma's
powered by Selexis®, for premium cell line development
Creating Stable, High-Yield, and Clonal Mammalian Cell Lines
Advanced Cell Line Development for New Biologics
The SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the new biologics continuum, spanning discovery to commercialization.
By combining our proprietary SUREtechnology Platform with our world-class expertise, our CLD services significantly reduce the time, effort, and cost associated with the development of high-performance mammalian cell lines for therapeutic protein production. As a cornerstone of the SUREtechnology Platform, the KBI SURE CHO-M Cell Line™ is a proprietary, high-performance cell line derived from CHO-K1 cells and used for the production of biotherapeutics. The SURE CHO-M Cell Line was specifically developed to overcome protein expression bottlenecks.
Explore More Mammalian:
Fill out the form below to get in touch with our team of experts.
Frequently Asked Questions, Answered
SUREtechnology Platform™ tools and technologies FAQs
Do you have a proprietary CHO cell line that is used for transfections?
How do you address cells and best clone selection? Are you using FACS, MACSQuant® Tyto® or Berkeley Lights?
Do vectors contain an amplification cassette, such as DHFR or the GS system?
Can you conduct genomic characterization to support RCB generation?
Do you have CHO host cell lines that have been adapted or modified to address secretion issues or to perform directed post-translational modifications available?
Does the SUREtechnology Platform use serum-free or chemically defined media and feed from commercial suppliers in large quantities?
How is the SUREtechnology Platform different from other available technologies for generating high-expressing and stable mammalian research cell banks (RCBs)?
Experience and Pipeline FAQs
Could you describe some of the molecules you have worked with where an additional domain/molecule was appended to the Fc domain? Any challenges associated with expressing these molecules?
How does understanding of the process and use of the early candidate pools impact the final clone?
How many different types of pairing technologies have you worked with?
What is your experience using cell lines that produce afucosylated mAbs for enhanced Antibody-Dependent Cell-mediated Cytotoxicity (ADCC)?
Are there cell line stability issues when all auxiliary proteins and genes of interest are incorporated into the cell’s chromosomal DNA?
What is the typical (g/L) cell line productivity for mAb, fusion protein, bsAb, and alternative scaffold proteins using the SUREtechnology Platform?
Process and Workflow FAQs
For cell line stability studies, how many generations do you go out to?
How do you determine the copy number of your plasmid in the cells and how do you control this parameter?
Does the expression of a chaperone or other protein create a problem for FDA or EMEA approval?
After the contract is signed, what is the typical delay to get a project into the company’s CLD queue?
Bispecific Antibody (bsAb) Production FAQs
Fill out the form below to connect with our team of experts.
Explore More Mammalian Services & Capabilities
Never Miss Another Update!
Subscribe to KBI's Newsletter, The Pulse, to stay up-to-date on all the latest news, articles, and events from KBI Biopharma.